Abstract: A pharmaceutical preparation adhering to the skin, in particular a transdermal therapeutic system, for the release of the active substance 17-&bgr;-estradiol, contained therein in dissolved form being between its saturation concentration in equilibrium with a gas phase of less than 10% relative air humidity and its saturation concentration in equilibrium with a gas phase of more than 90% relative air humidity, in all matrix levels and, if present, also in an adhesive layer, characterized in that the estradiol quantity contained in in the preparation amounts to at least three times the saturation solubility measured at 95% relative air humidity, and that the air enclosed in the package is adjusted to a relative air humidity between 5% and below 0.5%.

Abstract: A process for the production of sheet-like administration forms by way of coating and drying a solvent-containing, spreadable mass on a substrate is characterized in that the drying takes place in a first drying stage at between 30 and 50° C., in a second drying stage at between 35 and 80° C., and in third drying stage at between 25 and 50° C.

Abstract: An active-substance-containing transdermal therapeutic system for the controlled release of estradiol or its pharmaceutically acceptable able derivatives alone or combined with gestagens consisting of a layer, an active-substance-containing reservoir which is bonded thereto and produced by using pressure sensitive adhesives, and a removable protective layer is characterized by the fact that the pressure sensitive adhesive comprises esters of colophony.

Abstract: An active-substance-containing transdermal therapeutic system for the controlled release of estradiol or its pharmaceutically acceptable derivatives alone or combined with gestagens consisting of a backing layer, an active-substance-containing reservoir which is bonded thereto and produced by using pressure sensitive adhesives, and a removable protective layer is characterized by the fact that the pressure sensitive adhesive comprises esters of colophony.

Abstract: Pharmaceutical composition comprising (S)-N-ethyl-3-[1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate in free base or acid addition salt form and an anti-oxidant. Said pharmaceutical compositions may be delivered to a patient using a transdermal delivery device.

Abstract: Pharmaceutical composition comprising (S)-N-ethyl-3-[1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate in free base or acid addition salt form and an anti-oxidant. Said pharmaceutical compositions may be delivered to a patient using a transdermal delivery device.

Abstract: A pharmaceutical preparation adhering to the skin, in particular a transdermal therapeutic system, for the release of the active substance 17-&bgr;-estradiol, contained therein in dissolved form being between its saturation concentration in equilibrium with a gas phase of less than 10% relative air humidity and its saturation concentration in equilibrium with a gas phase of more than 90% relative air humidity, in all matrix levels and, if present, also in an adhesive layer, characterized in that the estradiol quantity contained in in the preparation amounts to at least three times the saturation solubility measured at 95% relative air humidity, and that the air enclosed in the package is adjusted to a relative air humidity between 5% and below 0.5%.

Abstract: Pharmaceutical composition comprising (S)-N-ethyl-3-[1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate in free base or acid addition salt form and an antioxidant. Said pharmaceutical compositions may be delivered to a patient using a transdermal delivery device.

Abstract: An active ingredient-containing transdermal therapeutic system with a nonadhesive backing layer, with an active ingredient-containing reservoir layer and with a self-adhesive surface facing the skin, where appropriate with redetachable protecting layer, is characterized by an elastic or plastically extensible diffusible backing layer with a metal layer which acts as permeability barrier for auxiliaries and active ingredients in the reservoir layer and is formed by film growth, in particular a metallization layer.

Abstract: A pharmaceutical preparation adhering to the skin, in particular a TTS, for the release of the active substance 17-&bgr;-estradiol, the concentration of the estradiol contained therein in dissolved form being between its saturation concentration in equilibrium with a gas phase of less than 10% relative air humidity and its saturation concentration in equilibrium with a gas phase of more than 90% relative air humidity, in all matrix layers and, if present, also in an adhesive layer, characterized in that the estradiol quantity contained in the preparation amounts to at least three times the saturation solubility measured at 95% relative air humidity, and that the air enclosed in the package is adjusted to a relative air humidity between 5% and below 0.5%.

Abstract: An active substance-containing transdermal pharmaceutical preparation with a given size of contact surface, comprising a tack-free backing layer which is permeable to active substances and an adhesive layer adhering to the skin is characterized by the fact that the backing layer comprises at least a third of the total active substance amount contained in the preparation.

Abstract: An active-substance-containing transdermal therapeutic system for the controlled release of estradiol or its pharmaceutically acceptable derivatives alone or combined with gestagens consisting of a backing layer, an active-substance-containing reservoir which is bonded thereto and produced by using pressure sensitive adhesives, and a removable protective layer is characterized by the fact that the pressure sensitive adhesive comprises esters of colophony.

Abstract: The invention refers to a transdermal therapeutic system for the delivery of active agents to the human body.The backing layer consists of common pharmaceutical plastic layer laminates which require labeling, e.g. by printing. The problem to solve lies in toxicological, technological and drug law disadvantages of pigment- or varnish-printing.According to the invention, the coding does not consist of an ink- or pigment layer but in an effect on surface properties of the backing layer corresponding to the coding.

Abstract: A transdermal therapeutic system having a layered structure, comprising a backing layer (1) and at least one active substance-containing matrix layer (2), for storage purposes being placed onto a removable protective layer (4) coated with an abherent (3) is characterized in that said abherent (3) has a lower diffusion coefficient for the active substance used than the base materials used in the matrix layer (2) or in the matrix layers.

Abstract: This invention relates to a process for the production of a transdermal therapeutic system containing the active substance 17-.beta.-estradiol and optionally further active substances having a laminated structure positioned on a backing layer which is essentially impermeable to active substance and moisture, one or more matrix layers and optionally an adhesive layer, characterized in that at least one of the matrix layers or the adhesive layer contains anhydrous 17-.beta.-estradiol in crystalline form.

Abstract: The present invention provides a method for treating Alzheimer's Disease using a xanomeline transdermal formulation. The invention provides desired transdermal xanomeline patch formulations.

Abstract: A transdermal therapeutic system (TTS) comprising an active substance which is sensitive to hydrolysis, and having a layer-like structure comprising a backing layer impermeable to moisture and active substance, a matrix comprising the active substance, and optionally a protective layer covering the matrix is characterized in that the matrix contains a water-binding component.

Abstract: The invention concerns a transdermal therapeutic system comprising the active substance 17-.beta.-estradiol and optionally further active substances, with a laminated structure comprising a backing layer which is substantially impermeable to moisture and impermeable to active substance, one or more matrix layers and, where non-adhesive matrix layers are present, an adhesive layer, characterized in that the concentration of the dissolved estradiol in all matrix layers and, where an adhesive layer is present, in the adhesive layer lies between its saturation concentration in dry condition und its saturation concentration in moist condition, whereby the term "dry condition" is understood to mean that the base material is in equilibrium with a gas phase with less than 10% relative humidity and the term "moist condition" is understood to mean that the base material is in equilibrium with a gas phase with more than 90% relative humidity.

Abstract: A transdermal therapeutic system comprising the active substance estradiol and having a layered structure of a backing layer which is impermeable to active substances and moisture, and active substance-containing matrix, and, if necessary, a removable protective layer covering the matrix, is characterized by the fact that the matrix comprises glycerol either comprising a maximum of 1%-wt. of water or being substantially free from water.

Abstract: An active substance-containing adhesive patch with a pressure sensitive fixing device, containing at least one readily volatile ingredient, consisting of a substantially active substance-impermeable backing layer, at least two active substance-containing matrix layers and a removable protective layer, whereby the matrix layer containing the readily volatile active substance is laminated on a separately produced composite of one or more further matrix layers which are active substance-free, is characterized in that the first active substance-containing matrix layer consists of a spreadable molecularly disperse solution of the matrix base material in the readily volatile ingredient as the exclusive solvent, the composite which is obtained after laminating forming an active substance matrix that is as a whole shear-resistant after migration of the readily volatile ingredient into the composite.